 Cosela is an FDA-approved myelosuppressive agent given before chemotherapy in patients with extensive-stage small cell lung cancer. Cosela may potentially alter the tumor microenvironment and improve T-cell function, this is being explored in a method of action phase 2 study with results expected in the 2nd half of 2022. 